National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
College of Medicine, Zhejiang University, Hangzhou, China.
Mycoses. 2021 Jun;64(6):656-667. doi: 10.1111/myc.13261. Epub 2021 Mar 2.
The effects of cryptococcemia on patient outcomes in those with or without HIV remain unclear.
One hundred and seventy-nine cryptococcemia patients were enrolled in this retrospective study. Demographic characteristics, blood test results and outcome were compared between the two groups.
The diagnosis time of Cryptococcus infection was 2.0(0-6.0) days for HIV-infected patients, 5.0 (1.5-8.0) days for HIV-uninfected patients (p = .008), 2.0 (1.0-6.0) days for cryptococcal meningitis (CM) patients and 6.0 (5.0-8.0) days for non-CM patients (p < .001). HIV infection [adjusted odds ratio (AOR) (95% confidence interval): 6.0(2.3-15.9)], CRP < 15 mg/L [AOR:3.7(1.7-8.1)) and haemoglobin > 110 g/L [AOR:2.5(1.2-5.4)] were risk factors for CM development. Forty-six (25.7%) patients died within 90 days. ICU stay [AOR:2.8(1.1-7.1)], hypoalbuminemia [AOR:2.7(1.4-5.3)], no anti-cryptococcal treatment [AOR:4.7(1.9-11.7)] and altered consciousness [AOR:2.4(1.0-5.5)] were independent risk factors for 90-day mortality in all patients. HIV infection did not increase the 90-day mortality of cryptococcemia patients when anti-Cryptococcus treatment was available. Non-Amphotericin B treatment [AOR:3.4(1.0-11.2)] was associated with 90-day mortality in HIV-infected patients, but age ≥ 50.0 years old [AOR:2.7(1.0-2.9)], predisposing disease [AOR:4.1(1.2-14.2)] and altered consciousness [AOR:3.7(1.1-12.9)] were associated with 90-day mortality in HIV-uninfected patients who accepted anti-Cryptococcus treatment.
HIV infection increased the incidence of CM rather than mortality in cryptococcemia patients. The predictive model was completely divergent in HIV-infected and HIV-uninfected patients, suggesting that novel strategies for diagnosis and treatment algorithms are urgently needed.
隐球菌血症对 HIV 感染者和非 HIV 感染者预后的影响尚不清楚。
本回顾性研究纳入了 179 例隐球菌血症患者。比较了两组患者的人口统计学特征、血液检查结果和结局。
HIV 感染者隐球菌感染的诊断时间为 2.0(0-6.0)天,HIV 阴性者为 5.0(1.5-8.0)天(p=0.008),隐球菌性脑膜炎(CM)患者为 2.0(1.0-6.0)天,非 CM 患者为 6.0(5.0-8.0)天(p<0.001)。HIV 感染[调整后的优势比(95%置信区间):6.0(2.3-15.9)]、CRP<15mg/L[调整后的优势比:3.7(1.7-8.1)]和血红蛋白>110g/L[调整后的优势比:2.5(1.2-5.4)]是 CM 发展的危险因素。46 例(25.7%)患者在 90 天内死亡。入住 ICU[调整后的优势比:2.8(1.1-7.1)]、低白蛋白血症[调整后的优势比:2.7(1.4-5.3)]、未接受抗隐球菌治疗[调整后的优势比:4.7(1.9-11.7)]和意识改变[调整后的优势比:2.4(1.0-5.5)]是所有患者 90 天死亡的独立危险因素。在有抗隐球菌治疗的情况下,HIV 感染并未增加隐球菌血症患者的 90 天死亡率。非两性霉素 B 治疗[调整后的优势比:3.4(1.0-11.2)]与 HIV 感染者的 90 天死亡率相关,但年龄≥50.0 岁[调整后的优势比:2.7(1.0-2.9)]、基础疾病[调整后的优势比:4.1(1.2-14.2)]和意识改变[调整后的优势比:3.7(1.1-12.9)]与接受抗隐球菌治疗的 HIV 阴性患者的 90 天死亡率相关。
HIV 感染增加了隐球菌血症患者发生 CM 的几率,而非死亡率。HIV 感染者和非感染者的预测模型完全不同,这表明迫切需要制定新的诊断和治疗策略。